Literature DB >> 21328014

Kidney histologic alterations in α-Galactosidase-deficient mice.

Carmen Valbuena1, João Paulo Oliveira, Fátima Carneiro, Sandra Relvas, Mariana Ganhão, M Clara Sá-Miranda, Lorena G Rodrigues.   

Abstract

Fabry disease is a rare X-linked disorder caused by mutations in the α-galactosidase gene (GLA), the resultant deficiency of lysosomal α-galactosidase enzyme activity leading to systemic accumulation of globotriaosylceramide and other glycosphingolipids. GLA knockout mice ("Fabry mice") were generated as an animal model for Fabry disease but, as they do not manifest progressive chronic kidney disease (CKD), their relevance as a model for human Fabry nephropathy is uncertain. We evaluated the histological alterations in the kidneys of Fabry mice at different ages, as contrasted to those observed in wild-type mice. Furthermore, we compared the renal histological alterations of Fabry mice to the kidney pathology reported in patients with Fabry disease at comparable age ranges and across different CKD stages, using a scoring system that has been developed for Fabry nephropathy. Fabry mice are phenotypically different from wild-type mice, displaying progressive age-related accumulation of glycosphingolipids in all types of renal cells. There were no statistically significant differences between Fabry mice and Fabry patients in the prevalence of glycosphingolipid storage per renal cell type with the exceptions of mesangial (higher in humans) and proximal tubular cells (higher in mice). However, Fabry mice lack the nonspecific histological glomerulosclerotic and interstitial fibrotic renal lesions that best correlate with progressive CKD in Fabry patients, and do not develop large podocyte inclusions. We postulate that the elucidation of the mechanisms underlying these species differences, may contribute important clues to a better understanding of the pathogenesis of Fabry nephropathy.

Entities:  

Mesh:

Year:  2011        PMID: 21328014     DOI: 10.1007/s00428-011-1051-8

Source DB:  PubMed          Journal:  Virchows Arch        ISSN: 0945-6317            Impact factor:   4.064


  30 in total

1.  Fabry disease: a morphologic study of 11 cases.

Authors:  Edgar G Fischer; Michael J Moore; Donna J Lager
Journal:  Mod Pathol       Date:  2006-06-23       Impact factor: 7.842

2.  Safety and efficacy of recombinant human alpha-galactosidase A replacement therapy in Fabry's disease.

Authors:  C M Eng; N Guffon; W R Wilcox; D P Germain; P Lee; S Waldek; L Caplan; G E Linthorst; R J Desnick
Journal:  N Engl J Med       Date:  2001-07-05       Impact factor: 91.245

3.  Early renal changes in hemizygous and heterozygous patients with Fabry's disease.

Authors:  M C Gubler; G Lenoir; J P Grünfeld; A Ulmann; D Droz; R Habib
Journal:  Kidney Int       Date:  1978-03       Impact factor: 10.612

4.  Enzymatic defect in Fabry's disease. Ceramidetrihexosidase deficiency.

Authors:  R O Brady; A E Gal; R M Bradley; E Martensson; A L Warshaw; L Laster
Journal:  N Engl J Med       Date:  1967-05-25       Impact factor: 91.245

Review 5.  Renal ultrastructural findings in Anderson-Fabry disease.

Authors:  Adalberto Sessa; Antonella Toson; Manuela Nebuloni; Francesco Pallotti; Ferdinando Giordano; Graziana Battini; Alessia Maglio; Mietta Meroni; Gilberto Calconi; Gabriele Bertolone; Pierlucio Gatti
Journal:  J Nephrol       Date:  2002 Mar-Apr       Impact factor: 3.902

6.  Enzyme replacement therapy in Fabry disease: a randomized controlled trial.

Authors:  R Schiffmann; J B Kopp; H A Austin; S Sabnis; D F Moore; T Weibel; J E Balow; R O Brady
Journal:  JAMA       Date:  2001-06-06       Impact factor: 56.272

7.  Kidney biopsy findings in heterozygous Fabry disease females with early nephropathy.

Authors:  Carmen Valbuena; Elísio Carvalho; Manuela Bustorff; Mariana Ganhão; Sandra Relvas; Rosete Nogueira; Fátima Carneiro; João Paulo Oliveira
Journal:  Virchows Arch       Date:  2008-09-04       Impact factor: 4.064

8.  Neurophysiological, behavioral and morphological abnormalities in the Fabry knockout mice.

Authors:  L G Rodrigues; M J Ferraz; D Rodrigues; M Pais-Vieira; D Lima; R O Brady; M M Sousa; M C Sá-Miranda
Journal:  Neurobiol Dis       Date:  2008-09-23       Impact factor: 5.996

9.  Structural organization of the human alpha-galactosidase A gene: further evidence for the absence of a 3' untranslated region.

Authors:  D F Bishop; R Kornreich; R J Desnick
Journal:  Proc Natl Acad Sci U S A       Date:  1988-06       Impact factor: 11.205

10.  Fabry's disease: alpha-galactosidase deficiency.

Authors:  J A Kint
Journal:  Science       Date:  1970-02-27       Impact factor: 47.728

View more
  8 in total

Review 1.  Lysosome dysfunction in the pathogenesis of kidney diseases.

Authors:  Kameswaran Surendran; Seasson P Vitiello; David A Pearce
Journal:  Pediatr Nephrol       Date:  2013-11-12       Impact factor: 3.714

2.  Low bone mineral density due to secondary hyperparathyroidism in the GlatmTg(CAG-A4GALT) mouse model of Fabry disease.

Authors:  Hiroki Maruyama; Atsumi Taguchi; Mariko Mikame; Hongmei Lu; Norihiro Tada; Muneaki Ishijima; Haruka Kaneko; Mariko Kawai; Sawako Goto; Akihiko Saito; Riuko Ohashi; Yuji Nishikawa; Satoshi Ishii
Journal:  FASEB Bioadv       Date:  2020-06-10

Review 3.  Lysosome function in glomerular health and disease.

Authors:  Catherine Meyer-Schwesinger
Journal:  Cell Tissue Res       Date:  2021-01-12       Impact factor: 4.051

Review 4.  Fibrosis: a key feature of Fabry disease with potential therapeutic implications.

Authors:  Frank Weidemann; Maria D Sanchez-Niño; Juan Politei; João-Paulo Oliveira; Christoph Wanner; David G Warnock; Alberto Ortiz
Journal:  Orphanet J Rare Dis       Date:  2013-08-06       Impact factor: 4.123

5.  Spontaneous Accumulation of Globotriaosylceramide (Gb3) in Proximal Renal Tubules in an ICR Mouse.

Authors:  Mayu Mutsuga; Yoshiji Asaoka; Yuko Togashi; Naoko Imura; Tomoya Miyoshi; Yohei Miyamoto
Journal:  J Toxicol Pathol       Date:  2013-12-26       Impact factor: 1.628

6.  Autophagy-lysosome pathway associated neuropathology and axonal degeneration in the brains of alpha-galactosidase A-deficient mice.

Authors:  Michael P Nelson; Tonia E Tse; Darrel B O'Quinn; Stefanie M Percival; Edgar A Jaimes; David G Warnock; John J Shacka
Journal:  Acta Neuropathol Commun       Date:  2014-02-14       Impact factor: 7.801

7.  Possible role of transforming growth factor-β1 and vascular endothelial growth factor in Fabry disease nephropathy.

Authors:  Mi Hee Lee; Eun Nam Choi; Yeo Jin Jeon; Sung-Chul Jung
Journal:  Int J Mol Med       Date:  2012-09-24       Impact factor: 4.101

8.  Medullary thick ascending limb impairment in the GlatmTg(CAG-A4GALT) Fabry model mice.

Authors:  Hiroki Maruyama; Atsumi Taguchi; Yuji Nishikawa; Chu Guili; Mariko Mikame; Masaaki Nameta; Yutaka Yamaguchi; Mitsuhiro Ueno; Naofumi Imai; Yumi Ito; Takahiko Nakagawa; Ichiei Narita; Satoshi Ishii
Journal:  FASEB J       Date:  2018-03-19       Impact factor: 5.191

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.